488 related articles for article (PubMed ID: 21703756)
1. Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
Mink S; Muroi C; Seule M; Bjeljac M; Keller E
Clin Neurol Neurosurg; 2011 Oct; 113(8):644-8. PubMed ID: 21703756
[TBL] [Abstract][Full Text] [Related]
2. Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats.
van Vliet EA; Edelbroek PM; Gorter JA
Epilepsia; 2010 Mar; 51(3):362-70. PubMed ID: 19674045
[TBL] [Abstract][Full Text] [Related]
3. Acute seizures due to a probable interaction between valproic acid and meropenem.
Coves-Orts FJ; Borrás-Blasco J; Navarro-Ruiz A; Murcia-López A; Palacios-Ortega F
Ann Pharmacother; 2005 Mar; 39(3):533-7. PubMed ID: 15701769
[TBL] [Abstract][Full Text] [Related]
4. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs).
Stepanova D; Beran RG
Seizure; 2014 May; 23(5):371-6. PubMed ID: 24630809
[TBL] [Abstract][Full Text] [Related]
5. Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.
Wojda E; Wlaz A; Patsalos PN; Luszczki JJ
Epilepsy Res; 2009 Oct; 86(2-3):163-74. PubMed ID: 19596559
[TBL] [Abstract][Full Text] [Related]
6. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem.
Fudio S; Carcas A; Piñana E; Ortega R
J Clin Pharm Ther; 2006 Aug; 31(4):393-6. PubMed ID: 16882111
[TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients.
Spencer DD; Jacobi J; Juenke JM; Fleck JD; Kays MB
Pharmacotherapy; 2011 Oct; 31(10):934-41. PubMed ID: 21950640
[TBL] [Abstract][Full Text] [Related]
8. Effect of concomitant administration of meropenem and valproic acid in an elderly Chinese patient.
Gu J; Huang Y
Am J Geriatr Pharmacother; 2009 Feb; 7(1):26-33. PubMed ID: 19281938
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome.
García C; Rubio G
Epilepsy Res; 2009 Aug; 85(2-3):318-20. PubMed ID: 19423296
[TBL] [Abstract][Full Text] [Related]
10. Levetiracetam as a treatment option in non-convulsive status epilepticus.
Rupprecht S; Franke K; Fitzek S; Witte OW; Hagemann G
Epilepsy Res; 2007 Mar; 73(3):238-44. PubMed ID: 17161587
[TBL] [Abstract][Full Text] [Related]
11. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
Otoul C; De Smedt H; Stockis A
Epilepsia; 2007 Nov; 48(11):2111-5. PubMed ID: 17651416
[TBL] [Abstract][Full Text] [Related]
12. Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.
Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M
Epilepsia; 2005 Sep; 46(9):1362-70. PubMed ID: 16146430
[TBL] [Abstract][Full Text] [Related]
13. Comparison of reproductive effects of levetiracetam and valproate studied in prepubertal porcine ovarian follicular cells.
Taubøll E; Gregoraszczuk EL; Tworzydø A; Wójtowicz AK; Ropstad E
Epilepsia; 2006 Sep; 47(9):1580-3. PubMed ID: 16981877
[TBL] [Abstract][Full Text] [Related]
14. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial.
Bähr O; Hermisson M; Rona S; Rieger J; Nussbaum S; Körtvelyessy P; Franz K; Tatagiba M; Seifert V; Weller M; Steinbach JP
Acta Neurochir (Wien); 2012 Feb; 154(2):229-35; discussion 235. PubMed ID: 21909835
[TBL] [Abstract][Full Text] [Related]
15. Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance.
Varoglu AO; Yildirim A; Aygul R; Gundogdu OL; Sahin YN
Clin Neuropharmacol; 2010 May; 33(3):155-7. PubMed ID: 20502135
[TBL] [Abstract][Full Text] [Related]
16. Onset of action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA).
Stefan H; Wang-Tilz Y; Pauli E; Dennhöfer S; Genow A; Kerling F; Lorber B; Fraunberger B; Halboni P; Koebnick C; Gefeller O; Tilz C
Epilepsia; 2006 Mar; 47(3):516-22. PubMed ID: 16529615
[TBL] [Abstract][Full Text] [Related]
17. Encephalopathy induced by levetiracetam added to valproate.
Bauer J
Acta Neurol Scand; 2008 May; 117(5):374-6. PubMed ID: 18081909
[TBL] [Abstract][Full Text] [Related]
18. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Kerkhof M; Dielemans JC; van Breemen MS; Zwinkels H; Walchenbach R; Taphoorn MJ; Vecht CJ
Neuro Oncol; 2013 Jul; 15(7):961-7. PubMed ID: 23680820
[TBL] [Abstract][Full Text] [Related]
19. Lacosamide Lowers Valproate and Levetiracetam Levels.
Tountopoulou M; Weschke B; Kaindl AM
Neuropediatrics; 2017 Jun; 48(3):188-189. PubMed ID: 28324910
[TBL] [Abstract][Full Text] [Related]
20. Incidence of delayed seizures, delayed cerebral ischemia and poor outcome with the use of levetiracetam versus phenytoin after aneurysmal subarachnoid hemorrhage.
Karamchandani RR; Fletcher JJ; Pandey AS; Rajajee V
J Clin Neurosci; 2014 Sep; 21(9):1507-13. PubMed ID: 24919470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
